↓ Skip to main content

Dove Medical Press

Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies

Overview of attention for article published in Patient preference and adherence, August 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

policy
1 policy source
twitter
3 X users

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
18 Mendeley
Title
Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies
Published in
Patient preference and adherence, August 2016
DOI 10.2147/ppa.s112297
Pubmed ID
Authors

Pareen Vora, Montse Soriano-Gabarró, Kiliana Suzart, Gunnar Persson Brobert

Abstract

The risk of venous thromboembolism (VTE) recurrence is high following an initial VTE event, and it persists over time. This recurrence risk decreases rapidly after starting with anticoagulation treatment and reduces by ~80%-90% with prolonged anticoagulation. Nonpersistence with anticoagulants could lead to increased risk of VTE recurrence. This systematic review aimed to estimate persistence at 3, 6, and 12 months with anticoagulants in patients with VTE, and to evaluate the risk of VTE recurrence in nonpersistent patients. PubMed and Embase(®) were searched up to May 3, 2014 and the search results updated to May 31, 2015. Studies involving patients with VTE aged ≥18 years, treatment with anticoagulants intended for at least 3 months or more, and reporting data for persistence were included. Proportions were transformed using Freeman-Tukey double arcsine transformation and pooled using the DerSimonian-Laird random-effects approach. In total, 12 observational studies (7/12 conference abstracts) were included in the review. All 12 studies either reported or provided data for persistence. The total number of patients meta-analyzed to estimate persistence at 3, 6, and 12 months was 71,969 patients, 58,940 patients, and 68,235 patients, respectively. The estimated persistence for 3, 6, and 12 months of therapy was 83% (95% confidence interval [CI], 78-87; I (2)=99.3%), 62% (95% CI, 58-66; I (2)=98.1%), and 31% (95% CI, 22-40; I (2)=99.8%), respectively. Only two studies reported the risk of VTE recurrence based on nonpersistence - one at 3 months and the other at 12 months. Limited evidence showed that persistence was suboptimal with an estimated 17% patients being nonpersistent with anticoagulants in the crucial first 3 months. Persistence declined over 6 and 12 months. Observational data on persistence with anticoagulation treatment, especially direct oral anticoagulants, in patients with VTE and its effect on risk of VTE recurrence were scarce and further research is required.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 17%
Student > Bachelor 3 17%
Other 2 11%
Researcher 2 11%
Student > Master 2 11%
Other 5 28%
Unknown 1 6%
Readers by discipline Count As %
Medicine and Dentistry 9 50%
Pharmacology, Toxicology and Pharmaceutical Science 2 11%
Economics, Econometrics and Finance 1 6%
Social Sciences 1 6%
Engineering 1 6%
Other 0 0%
Unknown 4 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2020.
All research outputs
#6,929,769
of 25,373,627 outputs
Outputs from Patient preference and adherence
#459
of 1,757 outputs
Outputs of similar age
#110,984
of 381,036 outputs
Outputs of similar age from Patient preference and adherence
#25
of 78 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,757 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 381,036 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.